Yield10 Bioscience, Inc.
YTENUnlisted companyAbout Yield10 Bioscience, Inc.
Yield10 Bioscience (formerly Metabolix, Inc.) is a company developing new technologies to achieve improvements in crop yield to enhance global food security.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Yield10 Bioscience, Inc. timeline
- 1992
- 🏁
- 2002
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2006
- 🔔· approximateInitial public offering on Nasdaq
- 📈· approximateListed on Nasdaq as YTEN
- 2017
- ✎Renamed Yield10 Bioscience, Inc.Formerly Metabolix Inc.
- 2019
- 💰Record revenue of $1 millionFY2019, the highest of the 5 years on record.
Events of Yield10 Bioscience, Inc. from Wikidata, SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Yield10 Bioscience, Inc.
- Acquisitions and changes
- Delisted: the exchange removed its shares from listing (Form 25-NSE) on 19 July 2024.
Market cap history
World rank over time
Rank in USA: #5,380 (Jan 2022) · #5,580 (Dec 2022) · #5,363 (Jul 2023) · #4,685 (Jan 2024)
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2023 | — | — | $-14M | $-14M | — |
| Dec 2022 | $0M | -26.2% | $-13M | $-14M | -3015.6% |
| Dec 2021 | $1M | -23.8% | $-12M | $-11M | -1808.2% |
| Dec 2020 | $1M | -1.2% | $-10M | $-10M | -1276.3% |
| Dec 2019 | $1M | +44.6% | $-9M | $-13M | -1600.0% |
| Dec 2018 | $1M | -40.4% | $-9M | $-9M | -1639.3% |
| Dec 2017 | $1M | -19.0% | $-9M | $-9M | -1000.0% |
| Dec 2016 | $1M | — | $-10M | $-8M | -655.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2023 | $-10M | $0M | $-10M | $-1.82 | — |
| Dec 2022 | $-11M | $0M | $-12M | $-2.76 | — |
| Dec 2021 | $-9M | $0M | $-9M | $-2.33 | — |
| Dec 2020 | $-9M | $0M | $-9M | $-4.30 | — |
| Dec 2019 | $-9M | $0M | $-9M | $-35.50 | — |
| Dec 2018 | $-9M | $0M | $-9M | $-36.99 | — |
| Dec 2017 | $-8M | $0M | $-8M | $-3.29 | — |
| Dec 2016 | $-14M | $1M | $-15M | — | — |
Quarterly results
Latest quarter to Jun 2024: revenue $0M, net income $-3M. Lighter bars: fourth quarters worked out from the annual report.
SEC filings
- Dec 6, 20248-KCurrent reportBankruptcy · Restructuring costs · Directors or officers changed
- Nov 22, 20248-KCurrent reportShareholder vote
- Nov 12, 20248-KCurrent reportMaterial agreement · Shareholder vote · Other events
- Oct 31, 20248-KCurrent reportDirectors or officers changed
- Oct 3, 20248-KCurrent reportMaterial agreement · Directors or officers changed · Other events
- Sep 9, 20248-KCurrent reportMaterial agreement · New financial obligation
- Aug 14, 202410-QQuarterly report · period to Jun 2024
- Jul 23, 20248-KCurrent reportAgreement ended
- Jul 17, 20248-KCurrent reportMaterial agreement
- Jun 12, 20248-KCurrent reportBylaws amended
- Jun 10, 20248-KCurrent reportDirectors or officers changed · Shareholder vote
- May 28, 2024S-1/AIPO registration (amended)
Official filings of Yield10 Bioscience, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-14 M
- Net income
- $-14 M
For year ending December-2023 · source: SEC filing
Balance sheet
- Total assets
- $4 M
- Total liabilities
- $6 M
- Total equity
- $-2 M
As of December-2023
Brands of Yield10 Bioscience, Inc. (1)#
Bioplastic · since 2006
Source: Wikidata. Brands whose Wikidata item names Yield10 Bioscience, Inc. (or a subsidiary of it) as owner, maker or parent organization; each brand's page links to its item
Insider trading at Yield10 Bioscience, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Kristi SnellVP Research and CSO | Shares withheld for tax | -877 | $1.500 | $1 K | 6,999 | Form 4 |
| filed | Charles B. HaaserVP Finance and CAO | Shares withheld for tax | -731 | $1.500 | $1 K | 5,949 | Form 4 |
| filed | Lynne H. BrumVP Planning and Communications | Shares withheld for tax | -731 | $1.500 | $1 K | 5,867 | Form 4 |
| filed | Oliver P. PeoplesPresident and CEO, Director | Shares withheld for tax | -1,463 | $1.500 | $2 K | 12,634 | Form 4 |
| filed | Robert L. Van NostrandDirector | Grant or award | +11,924 | — | — | 48,635 | Form 4 |
| filed | Anthony J. SinskeyDirector | Grant or award | +20,561 | — | — | 64,274 | Form 4 |
| filed | Richard William HamiltonDirector | Grant or award | +41,118 | — | — | 72,598 | Form 4 |
| filed | Kristi SnellVP Research and CSO | Grant or award | +120,000 | $0.300 | $36 K | 129,022 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Yield10 Bioscience, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-24 reverse split ; 1-for-24 reverse split ; 10-for-1 split ; 1-for-6 reverse split
Bankruptcy filing: (8-K)
Fails to deliver
- : 745 shares at $0.66
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Yield10 Bioscience, Inc. scorecard#
Passes 0 of the 7 checks that could be worked out. Fiscal year 2023.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.82 vs -2.76Diluted EPS -1.82 in fiscal 2023 against -2.76 the year before (report's currency).
- ✗Net income higher than five years earlier-$14 M-$14 M in fiscal 2023 against -$9 M in 2018.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$14 MNet income -$14 M in fiscal 2023.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2023.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 2
- ✗Short-term assets cover short-term liabilities0.3×Current ratio 0.29 at the end of fiscal 2023.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2023.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year61.7%Diluted shares up 61.7% in fiscal 2023.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Agriculture Related, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Yield10 Bioscience, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 | FY 2015to Dec 31, 2015 | FY 2014to Dec 31, 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0.1−86.7%100% | 0.5−26.7%100% | 0.6−23.2%100% | 0.8−0.9%100% | 0.8+45.0%100% | 0.6−41.1%100% | 0.9−18.6%100% | 1.2−14.1%100% | 1.4r2.6−51.8%100% | 2.8—100% | |
| Cost of revenue | — | — | — | — | — | — | — | — | 0.7−55.5%48.9% | 1.5—52.9% | |
| Selling, general and administrative | 6.2+0.0%10257% | 6.2+0.8%1367% | 6.1+21.0%994% | 5.0+10.8%632% | 4.6−10.6%565% | 5.1r5.1−9.6%916% | 5.6−1.9%596% | 5.7−20.5%495% | 7.2r9.1−33.2%535% | 11—386% | |
| Total costs and expenses | 14+4.1%24128% | 14+13.0%3089% | 12+18.2%2004% | 10+10.7%1303% | 9.4−4.8%1167% | 9.9r9.8−3.4%1776% | 10−10.3%1083% | 11−17.5%984% | 14r26−53.4%1024% | 30—1058% | |
| Operating income | −14—−24028% | −13—−2989% | −12—−1904% | −9.6—−1203% | −8.6—−1067% | −9.3r−9.3—−1676% | −9.3—−983% | −10—−884% | −12r−24—−924% | −27—−958% | |
| Interest and finance income | — | — | — | — | 0.1−39.2%11.9% | 0.2—28.4% | — | — | — | — | |
| Other non-operating income (expense) | −0.0−193%−63.3% | 0.0−94.1%9.1% | 0.7—114% | −0.5—−67.7% | −4.6−3543%−572% | 0.1r0.1—24.1% | −0.1—−12.0% | −0.0−161%−3.3% | 0.1+1.6%4.6% | 0.1—2.2% | |
| Income before tax | −14—−24092% | −13—−2980% | −11—−1791% | −10—−1270% | −13—−1639% | −9.2r−9.2—−1652% | −9.4—−995% | −10—−887% | −12r−24—−921% | −29—−1025% | |
| Income tax | 0−100%0.0% | 0.2+333%34.7% | 0.0−35.7%5.9% | 0.1—7.0% | −0.3—−31.5% | 0—0.0% | 0—0.0% | −1.1—−94.7% | 0—0.0% | 0—0.0% | |
| Income from continuing operations | — | — | — | — | — | — | −9.4—−995% | −9.2—−793% | −12r−24—−921% | −27—−956% | |
| Income from discontinued operations | — | — | — | — | — | — | 0−100%0.0% | 1.6—137% | −11r0—−833% | −2.8—−98.8% | |
| Net income attributable to shareholders | −14—−24092% | −14—−3015% | −11—−1797% | −10—−1277% | −13—−1607% | −9.2r−9.2—−1652% | −9.4—−995% | −7.6—−656% | −24—−1754% | −30—−1055% | |
| Earnings per share, basic | -1.82—— | -2.76—— | -2.33—— | -4.30—— | -35.50—— | -36.99r-0.92—— | -3.29—— | -2.73r-0.27—— | -0.95—— | -2.88r-0.48—— | |
| Earnings per share, diluted | -1.82—— | -2.76—— | -2.33—— | -4.30—— | -35.50—— | -36.99r-0.92—— | -3.29—— | — | — | -0.48—— | |
| Shares, weighted average (basic) | 7.9+61.7%— | 4.9+3.9%— | 4.7+99.4%— | 2.4—— | — | — | — | — | — | 61—— | |
| Shares, weighted average (diluted) | 7.9+61.7%— | 4.9+3.9%— | 4.7+99.4%— | 2.4+550%— | 0.4+47.0%— | 0.2r9.9−92.4%— | 3.3+18.2%— | 2.8r28−88.9%— | 25−59.3%— | 61—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 1.1−54.7%27.3% | 2.4−55.8%29.1% | 5.3+55.7%26.1% | 3.4−36.8%23.6% | 5.4+79.2%32.4% | 3.0−79.1%23.3% | 14+98.2%85.8% | 7.3−40.4%68.0% | 12−38.8%71.8% | 20—86.6% | |
| Short-term investments | 0−100%0.0% | 2.0−81.3%24.6% | 11+69.8%52.2% | 6.3+10.2%43.2% | 5.7+108%34.1% | 2.7—21.2% | 0—0.0% | — | — | 0—0.0% | |
| Receivables | — | 0−100%0.0% | 0.2+90.7%0.8% | 0.1+19.4%0.6% | 0.1−23.4%0.4% | 0.1+74.1%0.7% | 0.1−18.2%0.3% | 0.1−72.3%0.6% | 0.2+429%1.4% | 0.0—0.2% | |
| Inventory | — | — | — | — | — | — | — | 0−100%0.0% | 0.1r0.4−91.3%0.3% | 0.6—2.5% | |
| Other current assets | 0.3−48.2%8.5% | 0.6+47.0%7.9% | 0.4−17.3%2.1% | 0.5+10.9%3.6% | 0.5+6.0%2.8% | 0.4+44.1%3.5% | 0.3−14.3%1.8% | 0.4−78.2%3.4% | 1.7+121%9.8% | 0.8—3.3% | |
| Current assets | 1.4−72.1%35.8% | 5.0−69.8%62.1% | 17+60.7%81.4% | 10−11.5%71.2% | 12+83.2%69.9% | 6.4−57.3%49.2% | 15+89.8%88.4% | 7.9−47.1%73.1% | 15r15−32.4%86.9% | 22—94.9% | |
| Property, plant and equipment | 0.5−29.3%14.0% | 0.8−12.9%9.6% | 0.9−3.4%4.4% | 0.9−25.9%6.3% | 1.2−10.3%7.4% | 1.4−10.0%10.7% | 1.5−11.5%9.1% | 1.7+1556%16.2% | 0.1r0.9−77.0%0.6% | 0.5—2.0% | |
| Right-of-use (leased) assets | 1.7−15.7%42.3% | 2.0−16.7%24.3% | 2.4−13.2%11.5% | 2.7−13.7%18.7% | 3.1−34.1%18.8% | 4.8—36.8% | — | — | — | — | |
| Long-term investments | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | — | — | — | |
| Total assets | 3.9−51.7%100% | 8.1−60.4%100% | 20+40.6%100% | 15−13.1%100% | 17+29.0%100% | 13r8.2−23.2%100% | 17+57.1%100% | 11−37.1%100% | 17−26.1%100% | 23—100% | |
| Accounts payable | 1.2+1003%30.8% | 0.1+31.3%1.3% | 0.1+38.3%0.4% | 0.1−78.5%0.4% | 0.3+138%1.7% | 0.1+53.9%0.9% | 0.1+35.7%0.5% | 0.1−53.3%0.5% | 0.1−64.0%0.7% | 0.3—1.4% | |
| Current liabilities | 4.9+202%125% | 1.6−7.1%19.9% | 1.7−4.5%8.5% | 1.8−17.8%12.5% | 2.2+34.5%13.2% | 1.6r1.5−30.9%12.7% | 2.4−13.9%14.1% | 2.8−29.5%25.7% | 3.9−6.7%22.9% | 4.2—18.1% | |
| Lease liabilities (non-current) | 1.5−26.5%39.0% | 2.1−21.9%25.7% | 2.7r2.6−16.0%13.0% | 3.2−12.6%21.8% | 3.6−35.6%21.6% | 5.6—43.4% | — | — | — | — | |
| Total liabilities | 6.4+73.4%164% | 3.7−16.0%45.6% | 4.4−12.0%21.5% | 5.0−76.0%34.4% | 21+186%124% | 7.3r2.5+115%56.0% | 3.4−22.8%20.0% | 4.4+7.9%40.7% | 4.1−6.4%23.8% | 4.3—18.8% | |
| Retained earnings | −414—−10600% | −400—−4944% | −386—−1891% | −375—−2583% | −365—−2183% | −352r−352—−2716% | −343—−2030% | −333—−3102% | −326—−1906% | −302—−1306% | |
| Shareholders' equity | −2.5−156%−63.6% | 4.4−72.5%54.4% | 16+68.1%78.5% | 9.5—65.6% | −4.1−172%−24.4% | 5.7r5.7−57.8%44.0% | 14+112%80.0% | 6.4−51.1%59.3% | 13−30.7%76.2% | 19—81.2% | |
| Total liabilities and equity | 3.9−51.7%100% | 8.1−60.4%100% | 20+40.6%100% | 15−13.1%100% | 17+29.0%100% | 13r8.2−23.2%100% | 17+57.1%100% | 11−37.1%100% | 17−26.1%100% | 23—100% | |
| Shares outstanding | 0.5r12−89.9%— | 4.9+1.3%— | 4.9+46.4%— | 3.3+257%— | 0.9+272%— | 0.3r10−97.2%— | 9.1+221%— | 2.8r28−89.6%— | 27r27+21.3%— | 23r135—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.3+10.3%483% | 0.3+19.5%58.4% | 0.2+20.9%35.8% | 0.2−10.3%22.8% | 0.2+3.6%25.2% | 0.2−4.9%35.3% | 0.2−60.0%21.8% | 0.5+94.3%44.4% | 0.3−47.7%19.6% | 0.5—18.1% | |
| Share-based compensation | 1.6−16.3%2653% | 1.9+13.6%423% | 1.7+127%273% | 0.7+12.7%92.5% | 0.7−44.5%81.4% | 1.2−15.3%212% | 1.4+64.5%148% | 0.8−60.2%73.2% | 2.1−6.5%158% | 2.3—81.3% | |
| Cash from operating activities | −10—−16780% | −11—−2534% | −9.3—−1507% | −8.7—−1084% | −8.7—−1074% | −8.8—−1574% | −8.2—−869% | −14r−15—−1243% | −22—−1619% | −25—−876% | |
| Capital expenditure | −0.0—−76.7% | −0.2—−34.2% | −0.2—−30.8% | −0.1—−9.5% | −0.1—−7.6% | −0.0—−7.6% | −0.0—−0.6% | −0.8—−64.9% | −0.7—−48.4% | −0.2—−6.1% | |
| Cash from investing activities | 1.9−77.2%3242% | 8.5—1894% | −4.6—−746% | −0.6—−80.7% | −3.0—−374% | −2.8—−501% | −0.0r0.1−100%−0.6% | 9.8—841% | −0.6−105%−45.5% | 12—417% | |
| Shares issued | — | 0−100%0.0% | 12+126%1953% | 5.3−62.3%664% | 14—1747% | 0−100%0.0% | 13—1411% | 0—0.0% | — | — | |
| Cash from financing activities | 6.9—11452% | −0.0−100%−8.2% | 16+116%2564% | 7.3−48.3%911% | 14+11831%1747% | 0.1−99.2%21.2% | 15—1618% | −0.3r0−102%−25.5% | 15−41.7%1089% | 25—901% | |
| Exchange-rate effect on cash | −0.0—−60.0% | −0.1—−12.0% | −0.0—−1.5% | −0.0—−4.6% | −0.0—−2.0% | −0.0—−4.5% | −0.0—−0.1% | — | — | — | |
| Change in cash | −1.3—−2147% | −3.0−256%−661% | 1.9—310% | −2.1−186%−258% | 2.4—297% | −11−262%−2059% | 7.1—748% | — | — | — | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 | Q2 FY2023to Jun 30, 2023 | Q1 FY2023to Mar 31, 2023 | Q4 FY2022to Dec 31, 2022 | Q3 FY2022to Sep 30, 2022 | Q2 FY2022to Jun 30, 2022 | Q1 FY2022to Mar 31, 2022 | Q4 FY2021to Dec 31, 2021 | Q3 FY2021to Sep 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 0.8+191%100% | 0.5—100% | 0.3+400%100% | 0*−100%— | 0−100%— | 0−100%— | 0.1−59.7%100% | 0.1*−42.8%100% | 0.1+20.7%100% | 0.1—100% | 0.1—100% | 0.2*—100% | 0.1—100% | |
| Selling, general and administrative | 6.2−2.0%822% | 2.0+20.0%445% | 1.4−19.1%458% | 1.3*−8.3%— | 1.5−1.3%— | 1.7+9.7%— | 1.7−0.5%2830% | 1.4*−7.8%1613% | 1.5−1.9%1368% | 1.5—1479% | 1.7—1146% | 1.5*—1001% | 1.5—1682% | |
| Total costs and expenses | 13−7.5%1779% | 3.7−0.4%812% | 2.7−29.0%913% | 3.2*−1.3%— | 3.7+2.8%— | 3.7+3.6%— | 3.9+11.2%6433% | 3.3*+5.5%3783% | 3.6+13.1%3244% | 3.5—3436% | 3.5—2329% | 3.1*—2053% | 3.2—3460% | |
| Operating income | −13—−1679% | −3.2—−712% | −2.4—−813% | −3.2*—— | −3.7—— | −3.7—— | −3.8—−6333% | −3.2*—−3683% | −3.5—−3144% | −3.4—−3336% | −3.3—−2229% | −3.0*—−1953% | −3.1—−3360% | |
| Other non-operating income (expense) | −0.1−348%−14.5% | −0.0—−7.8% | −0.0−278%−10.7% | −0.0*−163%— | −0.0−330%— | −0.0−800%— | 0.0—30.0% | 0.0*—34.5% | 0.0−98.6%9.0% | 0.0—1.9% | −0.0—−0.7% | −0.0*—−0.7% | 0.7—760% | |
| Income before tax | — | — | — | −3.3*—— | −3.7—— | −3.7—— | −3.8—−6303% | −3.2*—−3648% | −3.5—−3135% | −3.4—−3334% | −3.3—−2230% | −3.0*—−1953% | −2.4—−2600% | |
| Income tax | — | — | — | 0*−100%— | 0−100%— | 0−100%— | 0−100%0.0% | 0.1*+1073%148% | 0.0+50.0%8.1% | 0.0—8.7% | 0.0—6.0% | 0.0*—7.2% | 0.0—6.5% | |
| Net income attributable to shareholders | −13—−1694% | −3.2—−720% | −2.5—−824% | −3.3*—— | −3.7—— | −3.7—— | −3.8—−6303% | −3.3*—−3797% | −3.5—−3143% | −3.4—−3343% | −3.3—−2236% | −3.0*—−1961% | −2.4—−2607% | |
| Earnings per share, basic | — | -5.04—— | -4.77—— | — | -0.41—— | -15.42r-0.64—— | -18.16r-0.76—— | — | -0.71—— | -0.70—— | -0.68—— | — | -0.49—— | |
| Earnings per share, diluted | — | -5.04—— | -4.77—— | — | -0.41—— | -15.42r-0.64—— | -18.16r-0.76—— | — | -0.71—— | -0.70—— | -0.68—— | — | -0.49—— | |
| Shares, weighted average (basic) | 0.6+169%— | 0.6+169%— | 0.5+149%— | — | 9.0+82.5%— | 0.2r5.7−95.1%— | 0.2r5.0−95.7%— | — | 4.9+1.1%— | 4.9—— | 4.9—— | — | 4.9—— | |
| Shares, weighted average (diluted) | 0.6+169%— | 0.6+169%— | 0.5+149%— | — | 9.0+82.5%— | 0.2r5.7−95.1%— | 0.2r5.0−95.7%— | — | 4.9+1.1%— | 4.9—— | 4.9—— | — | 4.9—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 0.7—24.7% | 0.7−68.6%24.7% | 1.6−11.7%37.6% | 1.1−54.7%27.3% | 2.8−28.2%46.6% | 2.3−26.5%39.8% | 1.8−15.0%33.9% | 2.4−55.8%29.1% | 3.9−73.2%34.8% | 3.2—22.3% | 2.1—12.4% | 5.3—26.1% | 15—63.7% | |
| Short-term investments | — | — | — | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 2.0−81.3%24.6% | 3.5−10.8%30.9% | 7.0—48.9% | 11—62.1% | 11—52.2% | 3.9—17.0% | |
| Receivables | — | — | — | — | — | — | — | 0−100%0.0% | 0.0+54.2%0.3% | 0.0—0.2% | 0.1—0.7% | 0.2—0.8% | 0.0—0.1% | |
| Other current assets | 0.5—15.9% | 0.5−31.6%15.9% | 0.5−17.0%12.4% | 0.3−48.2%8.5% | 0.5+31.6%9.0% | 0.7+42.7%11.7% | 0.6+40.6%11.9% | 0.6+47.0%7.9% | 0.4−10.4%3.7% | 0.5—3.4% | 0.5—2.6% | 0.4—2.1% | 0.5—2.0% | |
| Current assets | 1.2—40.6% | 1.2−60.2%40.6% | 2.1−13.1%50.0% | 1.4−72.1%35.8% | 3.4−57.4%55.6% | 3.0−71.7%51.5% | 2.4−81.7%45.8% | 5.0−69.8%62.1% | 7.9−58.6%70.0% | 11—75.0% | 13—78.2% | 17—81.4% | 19—83.0% | |
| Property, plant and equipment | 0.4—14.6% | 0.4−34.8%14.6% | 0.5−31.9%11.5% | 0.5−29.3%14.0% | 0.6−29.3%9.8% | 0.7−25.9%11.3% | 0.7−24.3%13.4% | 0.8−12.9%9.6% | 0.8−7.0%7.5% | 0.9—6.3% | 0.9—5.5% | 0.9—4.4% | 0.9—3.9% | |
| Right-of-use (leased) assets | 1.3—43.7% | 1.3−29.9%43.7% | 1.5−17.7%36.0% | 1.7−15.7%42.3% | 1.8−14.3%29.3% | 1.9−14.4%31.5% | 1.9−17.8%34.8% | 2.0−16.7%24.3% | 2.1−15.7%18.3% | 2.2—15.1% | 2.3—13.2% | 2.4—11.5% | 2.4—10.7% | |
| Long-term investments | — | — | — | 0—0.0% | — | — | — | 0—0.0% | — | — | — | 0—0.0% | — | |
| Total assets | 3.0—100% | 3.0−49.4%100% | 4.2−20.5%100% | 3.9−51.7%100% | 6.0−46.4%100% | 5.9−58.9%100% | 5.3−68.8%100% | 8.1−60.4%100% | 11−50.9%100% | 14—100% | 17—100% | 20—100% | 23—100% | |
| Accounts payable | 2.4—79.8% | 2.4+407%79.8% | 1.6+233%38.8% | 1.2+1003%30.8% | 0.4+266%6.3% | 0.5+1846%8.0% | 0.5+1963%9.3% | 0.1+31.3%1.3% | 0.1+131%0.9% | 0.0—0.2% | 0.0—0.1% | 0.1—0.4% | 0.0—0.2% | |
| Current liabilities | 7.7—258% | 7.7+210%258% | 6.2+174%146% | 4.9+202%125% | 4.0+116%65.4% | 2.5+51.8%42.1% | 2.3+65.0%42.6% | 1.6−7.1%19.9% | 1.8+9.6%16.2% | 1.6—11.4% | 1.4—8.0% | 1.7—8.5% | 1.7—7.3% | |
| Lease liabilities (non-current) | 1.1—36.6% | 1.1−41.0%36.6% | 1.3−29.9%31.7% | 1.5−26.5%39.0% | 1.7−23.8%28.1% | 1.8−22.4%31.4% | 1.9−23.5%36.0% | 2.1−21.9%25.7% | 2.2−20.0%19.7% | 2.4—16.6% | 2.5—14.7% | 2.7r2.6—13.0% | 2.8—12.1% | |
| Total liabilities | 9.2—310% | 9.2+74.3%310% | 7.6+80.3%178% | 6.4+73.4%164% | 5.7+39.4%93.5% | 5.3+32.0%90.0% | 4.2+7.7%78.6% | 3.7−16.0%45.6% | 4.1−9.1%35.9% | 4.0—28.0% | 3.9—22.8% | 4.4—21.5% | 4.5—19.4% | |
| Retained earnings | −420—−14146% | −420—−14146% | −417—−9819% | −414—−10600% | −411—−6800% | −407—−6936% | −403—−7564% | −400—−4944% | −396—−3517% | −393—−2753% | −389—−2277% | −386—−1891% | −383—−1670% | |
| Shareholders' equity | −6.2—−210% | −6.2−1163%−210% | −3.3−390%−78.1% | −2.5−156%−63.6% | 0.4−94.6%6.5% | 0.6−94.3%10.0% | 1.1−91.3%21.4% | 4.4−72.5%54.4% | 7.2−60.9%64.1% | 10—72.0% | 13—77.2% | 16—78.5% | 18—80.6% | |
| Total liabilities and equity | 3.0—100% | 3.0−49.4%100% | 4.2−20.5%100% | 3.9−51.7%100% | 6.0−46.4%100% | 5.9−58.9%100% | 5.3−68.8%100% | 8.1−60.4%100% | 11−50.9%100% | 14—100% | 17—100% | 20—100% | 23—100% | |
| Shares outstanding | 0.6—— | 0.6−89.5%— | 0.6−87.4%— | 0.5r12−89.9%— | 12+141%— | 6.1+24.5%— | 5.1+3.8%— | 4.9+1.3%— | 4.9+1.1%— | 4.9—— | 4.9—— | 4.9—— | 4.9—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.3−3.2%36.1% | 0.1*−21.1%13.3% | 0.1−4.3%22.0% | 0.1*+10.6%— | 0.1*+4.3%— | 0.1*+10.1%— | 0.1+16.9%115% | 0.1*+20.0%75.9% | 0.1*+21.1%62.2% | 0.1*—67.0% | 0.1—39.6% | 0.1*—36.2% | 0.1*—62.0% | |
| Share-based compensation | 1.5−12.4%201% | 0.3*−12.9%76.2% | 0.4−7.6%134% | 0.4*−13.9%— | 0.4−15.2%— | 0.4−19.3%— | 0.4−16.6%727% | 0.4*−11.0%511% | 0.4+2.5%403% | 0.5r−0.5—474% | 0.5—351% | 0.5*—329% | 0.4—474% | |
| Cash from operating activities | −5.8—−773% | −0.6*—−128% | −0.9—−301% | −1.7*—— | −2.6*—— | −3.1*—— | −2.7—−4445% | −3.1*—−3520% | −2.7*—−2434% | −2.5*—−2464% | −3.1—−2082% | −2.5*—−1635% | −2.0*—−2165% | |
| Capital expenditure | — | 0*—0.0% | 0—0.0% | −0.0*—— | — | −0.0*—— | −0.0—−15.0% | 0*—0.0% | −0.0*—−18.9% | −0.0*—−18.4% | −0.1—−76.5% | −0.0*—−27.6% | −0.0*—−12.0% | |
| Cash from investing activities | −0.0−100%−2.5% | 0*—0.0% | 0−100%0.0% | −0.0*−101%— | 0.0*−100.0%— | −0.0*−100%— | 2.0—3303% | 1.5*—1724% | 3.5*+247%3148% | 3.6*—3511% | −0.1—−59.1% | −6.8*—−4478% | 1.0*—1093% | |
| Shares issued | — | — | — | — | — | — | 0.2—303% | — | — | — | 0—0.0% | — | — | |
| Cash from financing activities | 4.0+5.9%530% | −0.3*−109%−72.4% | 1.2+759%404% | 0*—— | 3.1*—— | 3.6*—— | 0.1—235% | 0*—0.0% | −0.0*—−20.7% | 0*—0.0% | −0.0—−9.4% | 0*—0.0% | −0.0*—−21.7% | |
| Exchange-rate effect on cash | −0.0—−1.9% | 0.0*—0.2% | 0.0—1.3% | −0.0*—— | −0.0*—— | −0.0*—— | −0.0−200%−5.0% | −0.0*−233%−4.6% | −0.0*—−24.3% | −0.0*—−25.2% | 0.0—2.0% | 0.0*—2.0% | −0.0*—−18.5% | |
| Change in cash | — | — | — | −1.7*—— | 0.5*−35.2%— | 0.5*−49.9%— | −0.5—−912% | −1.6*—−1800% | 0.7*—668% | 1.1*—1021% | −3.2—−2148% | −9.3*—−6111% | −1.0*—−1112% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2024. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Yield10 Bioscience, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Bankruptcy or receivership 1 · Delisting notice 5 · Auditor changed 2 · Restructuring 2 · Directors and officers 5 · Material agreement 6 · Agreement ended 1 · New debt 1 · Bylaws or fiscal year changed 2 · Shareholder vote 4 · Results announced 3
| Filed | What happened | Filing |
|---|---|---|
| Bankruptcy or receivershipRestructuringDirectors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementShareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersMaterial agreement | 8-K | |
| Material agreementNew debt | 8-K | |
| Agreement ended | 8-K | |
| Material agreement | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K/A | |
| Auditor changed | 8-K | |
| Delisting notice | 8-K | |
| Auditor changed | 8-K | |
| RestructuringDirectors and officers | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Dec 6, 2024
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2016 | · | · | · | · | · | · | 45 | · | · | · | · | · | 45 |
| 2014 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2012 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 65% of workforce | Restructuring planSEC 8-K | “("Yield10" or the "Company") approved the full or partial furlough of approximately 65% of its workforce, most of whom are located in the Company's U.S. facility.” | Filing | |
| 45 people | Restructuring planSEC 8-K | “As part of the restructuring, Metabolix will discontinue its biopolymer operations and eliminate approximately 45 positions in its biopolymer operations and corporate organization,…” | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Yield10 Bioscience, Inc. compares in Agriculture Related
- Revenue growth-26.2% · higher than 10% of 21
Peer comparison · Agriculture Related
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Yield10 Bioscience, Inc.🇺🇸 | $3 M | — | — | -26.2% |
| Corteva, Inc.🇺🇸 | $51.2 B | 67.4× | 4.3% | +2.9% |
| Nutrien Ltd.🇨🇦 | $33.0 B | 14.6× | 8.4% | +3.5% |
| Qinghai Salt Lake Industry Co., Ltd🇨🇳 | $22.2 B | 18.1× | 54.7% | — |
| Zangge Holding Company🇨🇳 | $18.1 B | 32.4× | — | — |
| CF Industries Holdings, Inc.🇺🇸 | $17.7 B | 6.9× | 32.2% | +19.3% |
| Saudi Arabian Fertilizers Company🇸🇦 | $15.5 B | 13.5× | 33.0% | -17.3% |
| Yara International ASA🇳🇴 | $11.4 B | 8.3× | 8.8% | — |
| Shandong Hualu-Hengsheng Chemical Co., Ltd.🇨🇳 | $8.4 B | 17.5× | 10.7% | — |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Corteva, Inc.$51.2 B
- Nutrien Ltd.$33.0 B
- Qinghai Salt Lake Industry Co., Ltd$22.2 B
- Zangge Holding Company$18.1 B
- CF Industries Holdings, Inc.$17.7 B
- Saudi Arabian Fertilizers Company$15.5 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2023
- Balance sheet:
- As of December-2023
- Profile updated:
- Nov 14, 2026
Figures from SEC filing, Wikidata, value.today research, Wikipedia; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Yield10 Bioscience, Inc.? Verify and update this profile — free
Show Yield10 Bioscience, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.